Efficacy of stiripentol in Dravet syndrome with or without SCN1A mutations

By |2018-01-23T11:23:03-05:00October 31st, 2017|Categories: DSF Research Review|Tags: |

(Cho et al. 2017)  This small study of 32 patients with clinically-diagnosed Dravet syndrome sought to determine whether stiripentol's efficacy differed among those with and without SCN1A mutations. 15 patients had definite SCN1A mutations, and 17 had variants of unknown significance or benign variants. The severity of DS did not differ significantly between the two groups. Stiripentol [...]

Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet Syndrome Treated with Stiripentol, Valproate and Clobazam Combination Therapy

By |2017-10-05T16:26:15-05:00October 5th, 2017|Categories: DSF Research Review|Tags: , |

(Peigne S, et al. 2017) Although stiripentol has been used to treat patients with Dravet syndrome for several years, its pharmacokinetics (how the body processes the medication after a dose) are not always well understood by prescribing physicians. In this study, 35 patients with Dravet syndrome who were already taking clobazam, sodium valproate, and stiripentol [...]

Stiripentol in the management of epilepsy

By |2019-06-03T11:35:26-05:00May 8th, 2017|Categories: DSF Research Review|Tags: |

(Nickels KC, Wirrell EC 2017). This article reviews the current knowledge on stiripentol (Diacomit), as related to its mechanism of action (including its effects on the GABA-A receptor and inhibition of lactate dehydrogenase, a key enzyme in the brain used in the conversion of lactate to pyruvate); inhibition of several cytochrome P450 enzymes; safety and [...]